Sterling Financial Planning Inc. Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD)


Share on StockTwits

Sterling Financial Planning Inc. reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 600 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Sterling Financial Planning Inc.’s holdings in Gilead Sciences were worth $39,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Dodge & Cox increased its stake in Gilead Sciences by 35.7% during the fourth quarter. Dodge & Cox now owns 17,107,888 shares of the biopharmaceutical company’s stock worth $996,706,000 after acquiring an additional 4,500,035 shares during the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $767,548,000. UBS Asset Management Americas Inc. grew its stake in shares of Gilead Sciences by 4.6% in the fourth quarter. UBS Asset Management Americas Inc. now owns 8,997,053 shares of the biopharmaceutical company’s stock valued at $524,168,000 after buying an additional 392,859 shares in the last quarter. Morgan Stanley grew its stake in shares of Gilead Sciences by 18.4% in the fourth quarter. Morgan Stanley now owns 7,124,342 shares of the biopharmaceutical company’s stock valued at $415,063,000 after buying an additional 1,106,826 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Gilead Sciences by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 6,534,485 shares of the biopharmaceutical company’s stock valued at $380,700,000 after buying an additional 18,926 shares in the last quarter. Hedge funds and other institutional investors own 76.36% of the company’s stock.

Shares of Gilead Sciences stock traded up $0.46 during trading hours on Tuesday, reaching $66.26. 213,503 shares of the company’s stock were exchanged, compared to its average volume of 8,324,578. The company has a 50 day moving average of $65.14 and a two-hundred day moving average of $62.74. Gilead Sciences, Inc. has a fifty-two week low of $56.56 and a fifty-two week high of $81.76. The company has a current ratio of 3.25, a quick ratio of 3.15 and a debt-to-equity ratio of 1.65. The stock has a market cap of $83.43 billion, a P/E ratio of 67.84, a P/E/G ratio of 0.67 and a beta of 0.51.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.02. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 4.29%. The ex-dividend date is Monday, June 14th. Gilead Sciences’s payout ratio is presently 46.25%.

A number of research analysts recently commented on GILD shares. TheStreet raised Gilead Sciences from a “c” rating to a “b-” rating in a report on Tuesday, March 30th. SVB Leerink increased their target price on Gilead Sciences from $72.00 to $74.00 and gave the stock an “outperform” rating in a report on Friday. Credit Suisse Group increased their target price on Gilead Sciences from $65.00 to $66.00 and gave the stock a “neutral” rating in a report on Friday, February 5th. Guggenheim raised Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Monday, January 4th. Finally, Redburn Partners upgraded Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 30th. Ten research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $98.21.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 1,486 shares of the business’s stock in a transaction dated Thursday, March 11th. The shares were sold at an average price of $63.36, for a total value of $94,152.96. Following the transaction, the executive vice president now directly owns 29,166 shares in the company, valued at $1,847,957.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 1,975 shares of the business’s stock in a transaction dated Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total transaction of $133,134.75. Following the completion of the transaction, the executive vice president now owns 28,832 shares in the company, valued at $1,943,565.12. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Recommended Story: Asset Allocation

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.